KIAA1840 Gene Mutation Detection for AR-HSP Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods lack specificity and effectiveness for identifying mutations in the KIAA1840 gene associated with Autosomal Recessive Hereditary Spastic Paraplegia (AR-HSP), which hinders accurate diagnosis and genetic counseling for patients.
Innovation Solution
The identification of mutations in the KIAA1840 gene, including specific substitutions, deletions, and insertions, using isolated nucleic acids and antibodies that recognize these mutations, enabling targeted diagnostic approaches and potential therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used to identify mutations in the KIAA1840 gene, then the diagnostic process can be performed, but the specificity and effectiveness of the diagnosis is insufficient
Solution Approach 1:
The patent segments the diagnostic approach by identifying and targeting specific mutation types (substitutions, deletions, insertions) in the KIAA1840 gene separately, allowing for more precise detection of each mutation category rather than using a general diagnostic method
Solution Approach 2:
The patent performs preliminary identification and classification of mutation types in the KIAA1840 gene before final diagnosis, enabling targeted diagnostic strategies that improve both precision and reliability by pre-categorizing the genetic variations to be detected
Data Source
AI summary
An ex vivo method of diagnosing or predicting an hereditary spastic paraplegias (HSP) in a subject is provided which comprises detecting a mutation in the KIAA1840 gene or protein (spatacsin), wherein that mutation is indicative of an hereditary spastic paraplegias (HSP).